Elevance Health — Jan 23, 2025 release
Fiscal 2024 fourth-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001156039-25-000007
Showing in the filing
Year-End Medical Enrollment: Medicare Supplement
“Approximately 850”
Period
FY2025
Measure
Company-defined measure
Source
Guidance table
All guidance in this release · 31
Dividend for Q1 FY2025
“$1.71 per share”
Projected FY 2025 GAAP diluted EPS for FY2025
“$30.40 to $31.10”
Shareholders' earnings per diluted share for FY2025
“$30.40 to $31.10”
Adjusted shareholders' earnings per diluted … for FY2025
“$34.15 to $34.85”
Projected FY 2025 adjusted diluted EPS for FY2025
“$34.15 to $34.85”
Premium Revenue for FY2025
“Low double digit growth”
Product Revenue for FY2025
“Low single digit growth”
Service Fees for FY2025
“Approximately flat”
Total Operating Revenue for FY2025
“High single to low double digit growth”
Benefit Expense Ratio for FY2025
“89.1% +/- 50 bps”
Adjusted Operating Expense Ratio for FY2025
“10.4% +/- 50 bps”
Adjusted Operating Gain for FY2025
“$9.55 - $9.85 billion”
Net Investment income for FY2025
“$1,875 million”
Interest Expense for FY2025
“($1,475) million”
Amortization of Intangible Assets for FY2025
“($580) million”
Adjusted Effective Tax Rate for FY2025
“22.0% - 24.0%”
Diluted Shares for FY2025
“225 - 226 million”
Operating Cash Flow for FY2025
“Approximately $8.0 billion”
Operating Revenue Growth Rate: Health Benefits for FY2025
“High single digit growth”
Operating Revenue Growth Rate: Carelon Servi… for FY2025
“Greater than 50% growth”
GAAP Operating Margin vs. 2024: Health Benef… for FY2025
“(50) - (25) bps”
GAAP Operating Margin vs. 2024: CarelonRx for FY2025
“0 - 20 bps”
GAAP Operating Margin vs. 2024: Carelon Serv… for FY2025
“(100) - (50) bps”
Year-End Medical Enrollment: Commercial Fee-… for FY2025
“27,300 - 27,600”
Year-End Medical Enrollment: Commercial Risk… for FY2025
“5,150 - 5,350”
Year-End Medical Enrollment: Medicaid for FY2025
“8,600 - 8,900”
Year-End Medical Enrollment: Medicare Advant… for FY2025
“2,200 - 2,250”
Year-End Medical Enrollment: Medicare Supple… for FY2025
“Approximately 850”
Year-End Medical Enrollment: Federal Employe… for FY2025
“Approximately 1,650”
Year-End Medical Enrollment: Risk-Based for FY2025
“18,450 - 19,000”
Year-End Medical Enrollment: Total for FY2025
“45,750 - 46,600”
Exhibit 99.1 · the passage around this item
… earlier in the release
2024 Health Benefits 4.2% (50) - (25) bps CarelonRx 6.0% 0 - 20 bps Carelon Services 4.0% (100) - (50) bps 15 Elevance Health Membership Guidance Summary (Unaudited) Full Year 2024 Actual Full Year 2025 Outlook Year-End Medical Enrollment (in 000s) Commercial Fee-Based 27,199 27,300 - 27,600 Commercial Risk-Based 5,000 5,150 - 5,350 Medicaid 8,917 8,600 - 8,900 Medicare Advantage 2,066 2,200 - 2,250 Medicare Supplement 891 Approximately 850 Federal Employee Program 1,661 Approximately 1,650 Fee-Based 27,199 27,300 - 27,600 Risk-Based 18,535 18,450 - 19,000 Total 45,734 45,750 - 46,600 16 Forward-Looking Statements This document contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect our views about future events and financial performance and are generally not historical facts. Words such as “expect,” “feel,” “believe,” “will,” “may,” “should,” “anticipate,” “intend,” “estimate,” “project,” “forecast,” “plan” and similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to: financial projections and estimates and their underlying assumptions; statements regarding plans, objectives and expectations with respect to future operations, products and services; and statements regarding future performance. Such statements are subject to certain risks and uncertainties, many of which are difficult to predict and generally beyond our control, that could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking stat
later in the release …
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.